The face serves as a reflection of our thoughts and emotions, revealing not only how we feel but also how our health and age manifest over time. Recent research has introduced us to a groundbreaking tool that taps into this connection.
ADVERTISEMENT
ADVERTISEMENT
Some individuals might appear older than others, even at the same age—factors like illness, stress, and lifestyle choices contribute to this disparity.
A team of scientists at Mass General Brigham in the United States has developed FaceAge, a novel artificial intelligence (AI) tool designed to estimate a person’s biological age from just one photograph.
Biological age gives a clearer picture of the body’s physiological state and aging process, diverging from mere chronological age.
This technology has provided valuable insights into how patients respond to cancer and related treatments, identifying those more likely to survive or respond well to therapy.
With FaceAge, researchers discovered that cancer patients often exhibited facial aging approximately five years ahead of their chronological age, with this older appearance correlating to poorer survival outcomes following treatment.
Can FaceAge Predict Survival?
A recent study found that Face Aging Rate (FAR)—which tracks biological age changes through photographs—could serve as a valuable, non-invasive biomarker for cancer prognosis.
“Creating a Face Aging Rate from multiple routine facial images enables near real-time health tracking for individuals,” remarked Raymond Mak, co-senior and corresponding author of the study, as well as a radiation oncologist at Mass General Brigham Cancer Institute.
The researchers evaluated photographs from 2,276 cancer patients who underwent at least two rounds of radiation therapy at Brigham and Women’s Hospital between 2012 and 2023. The images were part of the standard clinical process for each therapy session.
The findings revealed that, on average, patients’ facial aging was 40% greater than their chronological age.
A higher FAR was associated with lower survival rates, and this effect was most pronounced when images were taken more than two years apart.
“Our findings indicate that monitoring FaceAge over time may fine-tune personalized treatment plans, enhance patient counseling, and help determine the intensity and frequency of follow-up care in oncology,” added Mak.
The study also introduced FaceAge Deviation (FAD), which measures how biologically old or young a person appears in a single photo compared to their chronological age. Those with elevated FAD and FAR values faced significantly worse survival outcomes.
However, FAR was found to be a more consistent predictor of survival over longer periods than FAD alone, indicating that ongoing measurements could be more dependable than isolated assessments.
The researchers noted that combining FAR with baseline FAD could yield a more comprehensive understanding of an individual’s changing health status.
“Tracking FaceAge using simple photographs offers a non-invasive, cost-effective method to gauge health,” commented Hugo Aerts, co-author and director of the AIM program at Mass General Brigham. “We aspire to explore how FaceAge can serve as a prognostic tool for other chronic conditions and for healthy individuals.”
Additionally, the team has established a web portal accessible to the public, allowing anyone to submit their facial image for a FaceAge evaluation, contributing to ongoing research efforts.
